N2O
PreclinicalSmall molecule
N2O is one of 46 small molecule programs targeting Agitation. It is currently in Preclinical.
2
Indications
3
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
350 competitors in Treatment
#DrugCompanyPhaseTrials
1Biltricide
BayerPreclinical
Dexilant
TakedaPreclinical
Alfenta
Jazz PharmaceuticalsPreclinical
Niclocide
BayerPreclinical
Minipress
PfizerPreclinical
Hivid
CConrado Roberto Hoffmann Filho
Preclinical
Clomid
FerringPreclinical
Aurlumyn
BBTG International Inc.
Preclinical
Lotemax
PPharmos
Preclinical
Norpramin
VValidus Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Agitation1 trial
Efficacy of Remifentanil in Preventing Emergence Agitation
Recruiting·SSaglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital·N/A·NCT06539013·99 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for N2O. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- TTel-Aviv Sourasky Medical Center